184 related articles for article (PubMed ID: 33859531)
1. The Relationship between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study.
Dai S; Ren P; Ren J; Yang L; Li W
Int J Med Sci; 2021; 18(10):2228-2234. PubMed ID: 33859531
[No Abstract] [Full Text] [Related]
2. Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.
Chen Y; Jin Y; Hu X; Chen M
Cancer Immunol Immunother; 2021 Oct; 70(10):2867-2876. PubMed ID: 33674986
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of circulating CD8
An N; Wang H; Jia W; Jing W; Liu C; Zhu H; Yu J
J Transl Med; 2019 Dec; 17(1):402. PubMed ID: 31796037
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].
Yan X; Zhao X; Jiao S; Sun S; Wu L; Wu Z
Zhongguo Fei Ai Za Zhi; 2012 Mar; 15(3):164-71. PubMed ID: 22429580
[TBL] [Abstract][Full Text] [Related]
8. Circulating low CD4
Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
[TBL] [Abstract][Full Text] [Related]
9. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
10. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
Ao M; Li P; Sun D; Li X; Xu S; Hao Y
J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
[TBL] [Abstract][Full Text] [Related]
11. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
12. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
14. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
15. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
[TBL] [Abstract][Full Text] [Related]
20. [Effect of Pembrolizumab on T Lymphocyte Subsets in Patients with Advanced
Non-small Cell Lung Cancer and Its Therapeutic Effect].
Wang Y; Wang Y; Jiang M; Zhao Y; Zhang X
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):182-187. PubMed ID: 33819968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]